Mechanism of Action
Enkephalinase Inhibition
Opiorphin inhibits NEP (neprilysin, CD10) and APN (aminopeptidase N, CD13), the two principal enzymes responsible for enkephalin degradation. Met-enkephalin and leu-enkephalin, released at pain synapses, normally have half-lives of seconds due to these enzymes. Opiorphin extends enkephalin lifetime, allowing greater activation of mu- and delta-opioid receptors at the synapse. This indirect mechanism avoids direct receptor binding and associated tolerance development.
Behavioral Pharmacology
In rodent pain models, opiorphin produces analgesia equivalent to morphine (3 mg/kg SC) at doses of 1 mg/kg IV. The effect is blocked by naloxone, confirming opioid receptor mediation. Opiorphin also shows antidepressant activity in forced swim and sucrose preference tests, consistent with the role of enkephalins in mood regulation.
Research Summary
Analgesia
PreclinicalOpiorphin (1 mg/kg IV) produces analgesia in rat formalin, hot plate, and tail flick tests comparable to 3 mg/kg morphine. Unlike morphine, tolerance development in repeated dosing studies appears slower, attributed to the indirect mechanism acting on endogenous enkephalins rather than exogenous receptor activation.
Antidepressant Effects
PreclinicalOpiorphin significantly reduces immobility in the forced swim test and restores hedonic behavior in chronic mild stress models, effects abolished by naloxone. This positions it as a potential non-addictive antidepressant acting through the endogenous opioid system, an attractive alternative to direct-acting opioid antidepressants.
Drug Development Potential
PreclinicalOpiorphin analogs with improved metabolic stability have been developed. Sialorphin (the rat homolog, VRFSR) and spinorphin (bovine homolog, LVVYPWTQRF) show similar enkephalinase inhibition. The neprilysin inhibition mechanism is validated clinically through sacubitril (LCZ696), a NEP inhibitor used for heart failure, demonstrating the target is druggable.
Calculate your Opiorphin dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Analgesia (rodent) | 1-3 mg/kg IV | Single injection | Intravenous |
| Antidepressant (rodent) | 1 mg/kg SC | Daily x 7 days | Subcutaneous |
| NEP/APN inhibition IC50 determination | 0.1-100 uM | Single assay | In vitro (enzyme assay) |
No human clinical data. Opiorphin is a research tool and lead compound. Not available as a human therapeutic. Rapid plasma degradation limits in vivo utility without structural modification.
Interactions
Safety Profile
No human safety data. Opiorphin inhibits neprilysin, which also degrades atrial natriuretic peptide (ANP), bradykinin, and substance P. Systemic NEP inhibition therefore raises theoretical concerns about blood pressure changes and edema (similar to sacubitril/valsartan side effects). No chronic toxicity data in animals exists. Rapid plasma degradation of the native pentapeptide limits systemic exposure.
References
- [1]Rougeot C, et al. Sialorphin, a natural inhibitor of rat membrane-bound neutral endopeptidase that controls mechanisms of intestinal glucose absorption and endogenous opioid mucosal defenses. J Physiol. 2003;547(Pt 3):767-779.
- [2]Wisner A, et al. Human Opiorphin, a natural antinociceptive modulator of opioid-dependent pathways. Proc Natl Acad Sci USA. 2006;103(47):17979-17984.
- [3]Rougeot C, et al. Endogenous opiorphin: first in-human study of a multitarget regulator of pain and depression. Trends Pharmacol Sci. 2010;31(11):521-528.